Efficacy and Safety of Atorvastatin for Chronic Subdural Hematoma: An Updated Systematic Review and Meta-Analysis

• Published in: World neurosurgery Vol. 188; pp. 177 - 184
• Main Authors: Monteiro, Gabriel de Almeida, Queiroz, Thomas Silva de, Gonçalves, Ocílio Ribeiro, Cavalcante-Neto, Joaquim Francisco, Batista, Sávio, Rabelo, Nicollas Nunes, Welling, Leonardo Christiaan, Figueiredo, Eberval Gadelha, Leal, Paulo Roberto Lacerda, Solla, Davi Jorge Fontoura
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2024
• Subjects: Atorvastatin; Chronic subdural hematoma; Meta-analysis; Recurrence; RR; Recurrence; RCT; Chronic subdural hematoma; CI; ADL; PRISMA; GOS; CSDH; Meta-analysis; MD; Atorvastatin; EPC
• ISSN: 1878-8750; 1878-8769; 1878-8769
• DOI: 10.1016/j.wneu.2024.05.069

Chronic subdural hematoma (CSDH) is a common neurological condition, especially in the elderly population. Atorvastatin has shown the potential to reduce the recurrence of CSDH and improve overall outcomes. New studies have emerged since the last meta-analysis, increasing the sample size and the variety of outcomes analyzed. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for studies comparing the use of atorvastatin in CSDH patients with a control group or placebo. The primary outcome was the recurrence of CSDH. Secondary outcomes of interest were hematoma volume, composite adverse effects, mortality, and neurological function, measured by the Glasgow Outcome Scale and Barthel index for activities of daily living. Seven studies, of which 2 were randomized controlled trials, were included, containing 1192 patients. Overall recurrence significantly decreased compared to the control group (risk ratio [RR] 0.46; 95% confidence interval [CI] 0.25–0.83; P=0.009). The benefits of atorvastatin were sustained in the subgroup analysis of patients who underwent initial conservative therapy (RR 0.40; 95% CI 0.22–0.70; P=0.001). However, there was no significant difference when atorvastatin was combined with surgical intervention (RR 0.53; 95% CI 0.21–1.32; P=0.17). Adverse effects were not increased by atorvastatin (RR 0.82; 95% CI 0.51–1.34; P=0.44). Atorvastatin might be beneficial in reducing CSDH recurrence, especially in conservative treatment patients. Atorvastatin was not significantly associated with adverse effects. Larger, higher-quality randomized studies are needed to adequately evaluate the efficacy, safety, and optimal dose of atorvastatin in CSDH patients.